Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 17/20 | 0.80 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373847 | 0.93 | CXCR3 (0.84) | CXCR3RAB9A | |
| SCHEMBL14373836 | 0.91 | CXCR3 (0.86) | CXCR3 | |
| SCHEMBL14373668 | 0.90 | CXCR3 (0.80) | CXCR3 | |
| SCHEMBL14373677 | 0.90 | CXCR3 (0.79) | CXCR3MAPT | |
| SCHEMBL14373832 | 0.90 | CXCR3 (0.85) | CXCR3 | |
| SCHEMBL14373845 | 0.90 | CXCR3 (0.94) | CXCR3 | |
| SCHEMBL14373672 | 0.89 | CXCR3 (0.84) | CXCR3 | |
| SCHEMBL14373381 | 0.89 | CXCR3 (0.84) | CXCR3 | |
| SCHEMBL14373680 | 0.89 | CXCR3 (0.83) | CXCR3NPC1RAB9A | |
| SCHEMBL14373803 | 0.89 | CXCR3 (0.83) | CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885NPC1 234/4885MAPT 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.